stella
beta
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma — Stella
Home
/
HER2 Negative
/
View on ClinicalTrials.gov
Recruiting
Back to HER2 Negative trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Qilu Hospital of Shandong University, Jinan, Shandong